Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial.

David Cella,Michelle D. Hackshaw,Gerard T. Vondeling,Lee Bennett,Diana Garbinsky,Kaku Saito,Masahiro Sugihara,Yung-Jue Bang,Kensei Yamaguchi,Kohei Shitara

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial.

2021

David Cella
Michelle D. Hackshaw
Gerard T. Vondeling
Lee Bennett
Diana Garbinsky
Kaku Saito
Masahiro Sugihara
Yung-Jue Bang
Kensei Yamaguchi
Kohei Shitara

4057Background: DESTINY-Gastric01 (NCT03329690) is a randomized, phase 2 study evaluating trastuzumab deruxtecan (T-DXd) in patients with HER2-positive advanced gastric cancer who progressed after ...

Keywords:

in patient
advanced gastric cancer
Internal medicine
Oncology
Medicine
Chemotherapy
Phases of clinical research
Toxicity
Trastuzumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations